Viridian Therapeutics, Inc.
VRDN · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $1 | $1 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -3.8% | -82.3% | -40.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -87,967.9% | -74,957% | -7,287.4% | -2,676% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -89,387.1% | -75,711.5% | -7,329.2% | -2,680.2% |
| EPS Diluted | -3.98 | -5.31 | -3.91 | -6.66 |
| % Growth | 25% | -35.8% | 41.3% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |